Pseudopodial and -arrestin-interacting proteomes from migrating breast cancer cells upon PAR2 activation.Nikolaos Parisis1,2,3, Gergana Metodieva1, Metodi V. Metodiev1, *
1Department of Biological Sciences/Proteomics Unit, University of Essex, Wivenhoe
Park, Colchester, Essex CO4 3SQ, United Kingdom;2Institute of Molecular Genetics (IGMM), CNRS, UMR5535, University of Montpellier I
and II, 34293 Montpellier, France; (current address)3Laboratory of Functional Proteomics, INRA, 34060 Montpellier, France (current
address)
*Author for correspondence ([email protected])
Running title: Pseudopodial and -arrestin proteomes
Key words: PAR-2; pseudopodium; beta-arrestin; cell migration; proteomics
123
4
5
6
7
8
9
10
11
12
Summary
Metastatic cancer cells form pseudopodia (PD) to facilitate their migration. The
proteinase-activated receptor-2 (PAR-2) transduces migratory signals from proteases, and
it forms protein complexes with -arrestin and other signalling molecules that are
enriched in pseudopodia. More generally, however, pseudopodial regulation is poorly
understood. Here, we purified the pseudopodial proteomes of breast cancer cells after
activation of the endogenous PAR-2 and we combined gel-based approaches with label-
free high-resolution mass spectrometry to identify proteins that accumulate at the
pseudopodia upon PAR-2-mediated migration. We identified >410 proteins in the cell
body and >380 in the pseudopodia upon PAR2 activation, of which 93 were enriched in
the pseudopodia. One of the pathways strongly enriched in the PD was the clathrin-
mediated endocytosis signalling pathway, highlighting the importance of the scaffolding
function of -arrestin in PAR-2 signalling via its endocytosis. We therefore
immunoprecipitated -arrestins, and with mass spectrometry we identified 418 novel
putative interactors. These data revealed novel -arrestin functions that specifically
control PAR-2-regulated signalling in migrating breast cancer cells but also showed that
some -arrestin functions are universal between GPCRs and cell types. In conclusion, this
study reveals novel proteins and signalling pathways potentially important for migration
of breast cancer cells.
Introduction
Cell migration is important in embryonic development, tissue homeostasis and in the
operation of the immune system. When it malfunctions, it can contribute to several
pathological conditions, including cancer metastasis [1]. Several chemotactic signals are
transduced into directional cell migration (chemotaxis) via numerous membrane
receptors and intracellular signalling pathways. The main characteristic of a chemotactic
cell is the formation of a leading edge, termed pseudopodium (PD), as a result of
spatiotemporally regulated accumulation of proteins towards the gradient [2]. The
identification of proteins important for gradient sensing, pseudopodia extension,
attachment and retraction is of vital importance for the understanding of chemotaxis.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Numerous proteins are involved in pseudopodia formation, such as plasma membrane
receptors, integrins, kinases and phosphatases, GTPases, scaffolding proteins and others,
important for actin dynamics, binding of the cytoskeleton to the extra-cellular matrix
(ECM) as well as the control of further signalling events [3-5]. However, the PD-
enriched proteins, which are dependent on the type of the chemoattractant and the
targeted receptor, as well as the cell type, are largely unknown.
In addition to their role in degrading the extracellular matrix, trypsin-like proteases
secreted from cancer cells have been implicated in the promotion of migration via the
proteolytic activation of the protease-activated receptor 2 (PAR-2) [6]. PAR-2 is a
ubiquitously but unevenly expressed GPCR receptor, which is activated by trypsin and
trypsin-like proteases, including tryptase, clotting factors VIIa and Xa, and has important
functions in immune system responses [7, 8]. PAR-2 has also been found overexpressed
in cancer cell lines, human tumours and in cells of the tumour microenvironment in situ
[9]. Ge et al. reported the secretion of biologically active trypsin-like proteases by the
MDA-MB-231 breast cancer cell line that can promote cell migration [10]. PAR-2-
mediated migratory signals have also been reported in pancreatic cells [11], human
melanoma and prostate carcinoma cells [12] and breast cancer cells [13, 14]. Similarly,
increase on the migration and ERK signalling of BT549 cells showed the activation of
PAR-2 by the clotting factors VIIa and Xa [15], suggesting that chronic inflammation
contributes to tumour metastasis. However, little is known about the downstream
signalling pathways regulated by this receptor. Following receptor activation, -arrestins
antagonize with G-proteins, bind to the receptor, uncouple it from G-proteins [16] and
transfer it via clathrin-coated pits to early endosomes [17]. Interestingly, during this -
arrestin-dependent endocytosis of PAR-2, a multiprotein signalling complex is formed
containing the receptor, -arrestin, raf-1 and ERK [18]. In this complex, -arrestin works
as a scaffold and retains ERK1/2 in the cytoplasm, thus ERK activity is predominantly
cytosolic. Notably, this protein complex is enriched in the pseudopodia, where it
promotes actin assembly along with other unidentified proteins [10, 19]. However, the
proteins that interact with -arrestin upon PAR-2 activation remain unknown.
In this study, we used a breast cancer cell line endogenously expressing the PAR-2
receptor and we applied gel-based, label-free proteomics approaches [20, 21] in order to
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
identify proteins and signalling pathways enriched in the pseudopodia. In addition, we
immunoprecipitated -arrestin and identified PAR-2-regulated -arrestin partners in breast
cancer cells (Fig. 1).
Materials and Methods
Materials
MCF-7 and MDA-MB-231 were a kind gift from Dr. Elena Klenova and HEK293S were
from Dr. Phillip Reeves. Vectors encoding FLAG-tagged -arrestin-1 or FLAG-tagged -
arrestin-2 (arr+FLAG) were kindly provided by Dr. Robert Lefkowitz and were
described elsewhere [22, 23]. PAR-2-activating synthetic peptide (P2AP) SLIGRL-NH2,
which is a more potent activator of human PAR-2 compared to SLIGKV-NH2 [24, 25],
was from Sigma. Anti-FLAG antibody was from Sigma and anti-phospho p44/p42
MAPK from Cell Signaling. All other antibodies were from Santa Cruz Biotechnology
and were used in 1/1000 dilution.
Cell culture and plasmid preparations
All cells, except HEK293, were cultured in Roswell Park Memorial Institute (RPMI;
Lonza) medium supplemented with Ultraglutamine 1, 10% foetal calf serum (FCS;
Biosera) and 1% antibiotic mixture (penicillin and streptomycin; Cambrex) at 37oC in a
humidified environment (5% CO2). Serum deprivation was performed in the same
medium but without FCS and for 12-16 hours. HEK293 were cultured in Dulbeco’s
Modified Eagle’s Medium (DMEM; Cambrex) with L-glutamine, supplemented with
10% FCS and 1% antibiotic mixture in 37oC and 5% CO2. All cell lines were used at a
low passage number. Bacterial (XL1-blue) cultures were grown in Luria Broth (LB)
medium and/or LB agar supplemented with ampicillin (100 g/ml; Sigma) or kanamycin
(50 g/ml; Sigma) with agitation at 250 rpm at 37oC. Bacterial transformations were
conducted according to Inoue et al., [26]. Plasmids were prepared by using commercial
kits (Qiagen or Fisher Scientific).
Western Blotting
Protein samples were analysed by SDS-PAGE in 10% home-cast polyacrylamide gels
with 4% stacking gels, according to Laemmli [27], and proteins were transferred onto
PVDF membranes (Millipore). The membrane was blocked with 5% milk or Odyssey
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
blocking buffer for 1 h. at room temperature (RT) and incubated with the appropriate
primary antibodies for 12-16 hours at 4oC. After 3 washes with a PBS solution
supplemented with Tween 20 (1%), the membrane was incubated with Alexa580- or
Alexa680- conjugated antibodies for 45 min. at RT. Finally, the membrane was scanned
by the Odyssey Infrared Imaging system (LI-COR). Band intensity was determined by
the Odyssey software and normalized to the loading control. Bar charts were created in
Microsoft Excel 2007.
Transfections
HEK293 cells were transfected with 10 g arr+FLAG by the calcium-phosphate method
in 90 mm tissue culture dishes. MCF-7 cells were transfected by using Lipofectamine
LTX following the manufacturer's instructions (Invitrogen). Fresh medium was added
after 24 hours and the cells were used for experiments or collected 48 hours post-
transfection. With these techniques, 90-100% transfection efficiency of HEK293 and 70-
80% transfection efficiency of MCF-7 was routinely achieved.
Under-agarose migration assay
The wells in the agarose gels were created by a special glass mould kindly provided by
Dr. Y. Mousseau [28]. Briefly, the glass mould was placed in the middle of a 60 mm
tissue culture dish and a 10 mL solution of 1% (w/v) agarose in PBS and serum-free
RPMI (1:1 ratio) was poured in the dish around the glass and left to polymerize for 8-12
min in a Class II tissue culture hood. The glass mould was removed and the 10 mL of
medium were added to equilibrate the gel. Before the experiment, 400 L of serum-free
RPMI were added in the central well and left in the incubator for at least one hour to
verify that there is not any leakage from the wells. Only agarose gels that did not leak
were subsequently used in the agarose migration assay. MCF-7 (4-8x104) cells were
seeded in the middle well, left to attach and serum-starved. After 16-20 hours, 50 M
P2AP was placed in a side well and serum-free medium alone was placed in the opposite
side well. Cell migration was monitored on an Olympus IMT-2 Phase contrast inverted
microscope and images were captured with an Olympus OM-2N camera.
Pseudopodia purification
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
For the separation of the pseudopodia from the cell bodies, both sides of several 24 mm
polycarbonate membranes with 3 m pore size were coated with collagen IV (6 g/cm2;
Sigma) and serum-starved MCF-7 cells (1.5x104) were seeded on the upper side. In the
lower chamber, 50 M P2AP was added for 0-120 minutes. Formed pseudopodia or cell
bodies were collected in SDS lysis buffer according to published protocols [4]. Lysates
were cleared by centrifugation and stored at -80oC.
Phosphopeptide enrichment
Equal amounts of CB and PD samples were loaded on an SDS-PAGE gel and the
electrophoresis was stopped as soon as the proteins migrated ≈0.5 mm in the resolving
gel. The gel was stained with Zinc sulfate, the band was sliced and subjected to in-gel
trypsin digestion. Peptide solutions were enriched for phosphorylated peptides with the
Magnetic Phosphopeptide Enrichment Kit (Clontech) on a magnetic separator, following
manufacturer's instructions.
Immunoprecipitations
MCF-7 or HEK293 cells were harvested with a cell scraper in 1% Triton X-100, 50 mM
Tris-HCl pH 6.8 supplemented with protease (PMSF, pepstatin, aprotinin) and
phosphatase (NaF, Na2VO3, Na4P2O7) inhibitors after rinsing with ice-cold PBS. Cells
were left on ice for 30 min. with periodical vortexing and sonicated for complete lysis
before being cleared by centrifugation at 14.000 rpm, 4oC for 20 min. Lysates were
mixed with agarose beads anti-FLAG M2 (Sigma) or protein A/G beads and incubated
for 12-16 hours at 4oC on a rotator. Unbound proteins were removed with 3-5 washes and
bound proteins were eluted twice with 3x FLAG peptide, according to manufacturer's
instructions, and subsequently with Laemmli buffer. For Western blot analysis, proteins
were seperated by 10% SDS-PAGE and were processed as described above. For MS/MS
analysis, the eluted proteins were separated by SDS-PAGE, the lanes were cut in 10
slices and in-gel digestion was performed with 20 g/mL trypsin (Trypsin Gold, Mass
Spectrometry Grade, Promega) according to Shevchenko et al., [29].
Mass spectrometric analysis
Tryptic peptides were injected onto an Ultimate II nano-LC (Dionex) coupled to Esquire
HCT quadrupole ion trap mass spectrometer (Bruker Daltonics) via online nano
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
electrospray ion source. Peptides were separated in a Pepmap 75, 75 m i.d., 150 mm
long reverse-phase column packed with 3 m C18 silica particles (Dionex). The elution
from the column and the data acquisition have been previously described [20]. The
conditions for MS/MS analysis with the Orbitrap Velos have been recently described
[21].
Bioinformatic analysis
The generated data were converted to mzXML files by using the compassXport software
(Bruker Daltonics) and MS/MS data were uploaded on and analysed by the
Computational Proteomics Analysis System (CPAS) pipeline [30] with Mascot or X!
Tandem as search engines. Peptide Prophet [31] and Protein Prophet [32] scores were
generated to provide statistical analysis of protein identification by the Transproteomic
Pipeline (TPP) from the Seattle Institute of Systems Biology, which was integrated into
the CPAS. The following criteria were used to establish the confidence of the identified
proteins: protein prophet ≥0.9, high peptide prophet scores (≥0.7), low Expect value,
assignment of most prominent peaks as b- or y- ions, experimental sequence-theoretical
sequence alignment, K or R as the most C-terminal residue, aspartic acid- or proline-
directed fragmentation. To avoid false-positive hits, only proteins matched with at least 2
peptides or 1 unique peptide were considered as true hits while all MS/MS spectra were
manually inspected. Relative abundance was estimated by the spectral counting method
[33]. For the pseudopodial proteins, pathway analysis, molecular function and biological
processes of proteins were obtained from GeneOntology (www.geneontology.org) and
pie charts were created in PANTHER classification system [34]. The trial version of the
Ingenuity Pathway Analysis program was used for functional annotations, signalling
pathway analysis and creation of bar charts [35]. For the -arrestin-interacting proteins,
we performed two biological replicates and two technical replicates. The PANTHER
classification system was used to classify proteins based on their molecular function and
PANTHER protein class. In the analyses, we used only proteins that were not identified
in the control experiment (transfection with an empty vector or untransfected cells) or
were identified with significantly higher (ten-fold) spectral counts in the transfected
conditions.
Results
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
Endogenous expression of PAR-2 in MCF-7 cells and activation of ERK cascade by
uniform concentrations of P2AP
In order to study PAR-2 signalling in its physiological context, we used MCF7 cells, a
breast cancer cell line which expresses PAR-2 endogenously (Fig. 2A). Signalling
downstream of PAR-2 is strongly associated with ERKs and has important roles in
migration [18]. The effect of chemotactic agents at uniform or gradient concentrations on
the ERK pathway is cell-type dependent [36]. In order to test whether uniform
concentrations of the PAR-2-activating peptide SLIGRL (P2AP) induce ERK
phosphorylation, MCF-7 (low invasive) and MDA-MB-231 (highly invasive) cells were
deprived of serum and then treated with P2AP or FCS for 0-120 min. As expected, the
addition of P2AP for 30 min in culture significantly induced the ERK pathway in both
cell lines and the pERK levels remained higher than basal over a time course of at least 2
hours (Fig. 2B). P2AP did not induce any change in the low levels of basal pERK in the
non-invasive CAMA and ZR-75 cells (data not shown). These results confirmed that
PAR-2 activation by uniform concentrations of P2AP induced the ERK pathway in MCF-
7 cells.
Migratory effect of P2AP on MCF-7 cells
Since MCF-7 cells responded well to uniform concentrations of P2AP with respect to
ERK activity upon PAR-2 activation and as this cell line is considered as low invasive
[37], we tested whether PAR-2 could sense gradient concentration of its ligand and
trigger the ERK pathway as well as cell migration. PAR-2 activation is known to enhance
migration of other breast cancer cells via the ERK pathway, including MDA-MB-231 and
MDA-MB-468, as well as of mouse embryonic fibroblast cells NIH3T3 [10, 18] and
there is one study that tested this in MCF-7 [14]. We studied the effect of PAR-2
activation on cell migration with the agarose migration assay. Indeed, even though the
cells did not migrate under the gel in the agarose migration assay, probably due to their
large size or their slow migration rate and their need for longer incubation times in order
to continue migrating under the agarose, they accumulated at the side of the well towards
P2AP (Fig. 3A). These results are consistent with Kamath et al. [14] and suggest that
MCF-7 cells sensed the gradient of P2AP, and the subsequent activation of PAR-2
promoted their migration.
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
Proteins and signalling pathways enriched in the pseudopodia of breast cancer cells.
The migration of cells is characterized by the extension of a leading edge and the
formation of a pseudopodium [3]. Since activation of PAR-2 promoted the migration of
MCF-7, we aimed to identify the proteins that accumulate at the pseudopodia of
migrating MCF-7 cells upon activation of PAR-2, by the method developed by Klemke
and colleagues [4]. First, we found the optimum timepoint to harvest the dynamic
structure of pseudopodia at the time they were formed. The P2AP was left in the lower
compartment for 0, 30, 60, 90 or 120 min and the PD were harvested. The protein
amounts in each time point were: low at 30 and 90 min. and almost minimal at 0 and 120
min. The highest amount of proteins was harvested at the 60 min suggesting that this is
the timepoint of pseudopodial formation (data not shown). Therefore, for the rest of the
study we stimulated the cells for 60 min before PD purification.
The efficiency of the purification was controlled with Western blots against the
poly[ADP-ribose]polymerase 1 (PARP-1). Accordingly, PARP-1 was enriched in the cell
body fractions and only trace amounts were detected in the pseudopodia fraction (Fig. 3C
upper panel). Similarly, the band that corresponds to histones was absent from the PD
fraction (Fig. 3B). These results showed the high efficiency of pseudopodia purification
from migratory MCF-7 cells. Next, the ERK levels in each compartment were measured.
Phospho-ERK1/2 levels were increased in both CB and PD upon PAR-2 activation by
2.4- and 2.8-fold, respectively (Fig. 3C lower panel and Fig. 3D). More detailed, pERK1
levels showed an increase of similar magnitude (2.95 and 3.05 times, respectively) while
pERK2 levels showed higher increase in the PD (2.16-fold) than in the CB (1.57-fold).
Two complementary workflows were used in order to identify PAR-2-regulated
pseudopodial proteins and pathways during MCF-7 cell migration: (i) the pools of
proteins from the pseudopodia and cell bodies were analysed by SDS-PAGE and the
entire lanes were sliced into 10 regions (Fig. 3B); (ii) the pools of proteins from the
pseudopodia and cell bodies were digested by trypsin and phosphopeptides were
enriched. Relative quantitation was performed with the spectral counting method;
proteins with PD/CB ratio ≥ 1.5 were considered enriched in the pseudopodium, whereas
those with a ratio ≤ 0.66 were considered to be rather excluded from the PD [4, 20, 33].
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
The sample fractionation at the protein level in workflow 1 was crucial for the
identification of 3.2 times more proteins compared to workflow 2. In total, 250 non-
redundant proteins were identified, of which 207 with workflow 1 and 63 with workflow
2 while 20 proteins were identified in both (that is 32% of the total proteins identified in
workflow 2). Comparative analysis of CB and PD fractions showed a total of 93 proteins
enriched in the PD, 117 proteins were rather depleted from PD, while 60 did not show
any significant change. To increase the confidence of the identification, of the 20 proteins
that overlapped in workflows 1 and 2, only those that showed identical enrichment
profiles in both workflows were considered as PD enriched proteins (Fig. 4 and Table 1).
Protein pathway analysis by the PANTHER Classification System [34] revealed the
pathways that are most represented by the enriched proteins. In the PD, some of those
were the apoptosis, interleukin or Huntington disease signalling pathways. Interestingly,
several other receptor signalling pathways, such as dopamine receptor, EGF, FGF and
PDGF, were also enriched in the PAR-2 mediated pseudopodia. In the CB, DNA
replication-related pathways as well as biosynthetic and metabolic pathways (arginine, O-
antigen, pyruvate and others) were enriched (Fig. 4). Furthermore, the breakdown of
biological processes of the PD-enriched proteins was as follows: cellular processes
(34.6%), transport (23.5%), cell communication (12.3%), cellular component
organization (21%), metabolic process (49.4%), developmental processes (22.2%) and
others (SI Fig. 3).
Identification of -arrestin-interacting proteins
Among the proteins found enriched in the pseudopodia of MCF-7 cells were the two
large adaptins of the clathrin-associated adaptor protein (AP) complex (AP-2 complex
subunit alpha-1 and subunit beta) as well as the clathrin heavy chain and coatomer
subunits, indicating the significance of clathrin-mediated endocytosis to pseudopodia
formation. The AP complex regulates the formation of the clathrin-coated vesicles, which
are sequestered by -arrestins, the important mediators of 7-TMR endocytosis. As PAR-2
is dependent on the scaffolding ability of -arrestins for PAR-2 endocytosis as well as for
downstream signalling, and the PAR-2-regulated -arrestin interactome is far from
complete, we aimed to identify the proteins that are sequestered by -arrestins and hence
to reveal novel -arrestin-dependent functions triggered by PAR-2 activation.
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
In order to achieve this, we transiently transfected MCF-7 cells with FLAG-tagged -
arrestin-1 or -arrestin-2 in MCF-7 cells with endogenous levels of PAR-2, and after
treatment with either P2AP, FCS or serum-free medium, the -arrestins and their
interacting partners were immunoprecipitated by using the FLAG purification system. As
controls, we performed parallel experiments with cells transfected with an empty vector
or untransfected. The proteins identified in these negative controls were considered as
background and excluded from further analyses (SI table 11). Furthermore, proteins that
are usual contaminants in proteomics experiments, such as keratins, albumin,
glyceraldehyde-3-phosphate dehydrogenase, heat shock protein, desmoplakin, or others
that interact unspecifically with the anti-FLAG beads, were excluded from our analyses.
With the above stringent criteria, we identified 418 proteins that co-immunoprecipitate
with -arrestins in all conditions. Of these, 223 interacted with -arrestin-1, 325 with -
arrestin-2 while several of them interacted with both. More specifically, 115 proteins
interacted with -arrestin-1 in uninduced conditions, and 35 of those interactions were
lost after treatment; 28 interacted only in FCS-treatment; 57 only in PAR-2 activating
conditions, while 23 interacted after both treatments (table 2 and SI table 9). Similarly,
with -arrestin-2, 186 proteins interacted in uninduced conditions and 84 of these were no
longer bound after treatment; 55 bound to -arrestin-2 only upon FCS treatment; 65 only
in PAR-2 activating conditions, while 19 interacted after both treatments (table 3 and SI
table 9). Finally, a number of proteins were found associated with one -arrestin in
untreated conditions, but upon treatment were found associated with the other -arrestin,
and vice versa.
In order to increase the confidence of our proteomics screen, we show by immunoblotting
that two of the identified protein (nucleophosmin and heat shock protein 70) co-
immunoprecipitate specifically with -arrestin-2 upon PAR-2 activation.
Canonical pathway analysis of -arrestin interactors
Using Ingenuity Pathway Analysis, we generated and compared the canonical pathways
of the proteins interacting with either -arrestin (SI Fig. 3). Interestingly, after PAR-2
activation, -arrestin-1 interactions are more abundant than -arrestin-2 in pathways of
cell junction signalling, gap junction signalling, intrinsic prothrombin activation pathway,
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
dendritic cell maturation. On the other hand, -arrestin-2 appears to be more involved in
interleukin signalling, actin cytoskeleton signalling, clathrin-mediated endocytosis or
other endocytic pathways, regulation of actin based motility by Rho, RhoA signalling,
RhoGDI signalling, protein kinase A signalling, granzyme A signalling, PI3K/AKT
signalling and others. We also used PANTHER to categorize proteins based on their GO
Molecular Function and Biological Process (SI Fig. 5A-I) as well as PANTHER Protein
Class (Tables 2, 3). In terms of GO Molecular Function, -arrestin-1-interacting proteins
in untreated cells have binding, catalytic, enzyme regulator, transcription factor and
structural molecule activities and when treated with P2AP, they are additionally involved
in receptor, motor and transporter activities. For β-arrestin-2-interacting proteins in
untreated cells, they are involved in the same activities as for -arrestin-1 in addition to
receptor and transporter activities and in PAR-2-activating conditions they are
additionally engaged with ion channel and translation regulator activities.
Discussion
Protease inhibitors have been used in the treatment of several pathologies, such as
asthma, emphysema, and others [8, 38], and over the past 10 years the possibility of using
protease inhibitors or PAR-2 antagonists as therapeutics in tumour metastasis has been
investigated [8]. Taking into consideration the recent finding that actively migrating
cancer cells secrete trypsin proteases [10] as well as the heterogeneous nature of cancer,
it is conceivable that final stage tumour cells, with an acquired ability to invade, secrete
proteases for ECM degradation as well as for promoting migration of other earlier stage
tumour cells. Therefore, identifying the molecular mechanisms that govern the PAR-2-
mediated metastasis of breast cancer cells is critical for the complete understanding of
this process.
By identifying proteins enriched in the pseudopodia of MCF-7 breast cancer cells, which
endogenously express the PAR-2 receptor, we cataloged the most important signalling
pathways represented in this cell line (Table 1 and Fig. 4). In addition, we identified a
number of putative -arrestin interactors downstream of the PAR-2 receptor (Tables 2 and
3). Several of these identified proteins interact with -arrestin upon angiotensin II type 1a
receptor (AT1A-R) activation in HEK293 cells, but the majority are novel suggesting that
they might be cancer-specific interactions during cancer metastasis.
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
It is generally accepted that a migrating cell requires spatiotemporal re-arrangement of
proteins that lead to the formation of a leading edge and a trailing back [2, 3]. It is shown
here that, in MCF-7 breast cancer cells, the ERK pathway is activated by uniform
concentrations of PAR-2-activating peptide (P2AP) and the levels remain high over a
course of at least 2 hours (Fig. 2B). This is also the case with the highly invasive MDA-
MB-231, consistent with the findings of Ge et al., [10] (Fig. 2B). Upon gradient
concentrations of P2AP, an increase in the pERK1/2 levels is observed in the entire cell
but there is no spatial difference in either total pERK1/2 or pERK1 activity in cell bodies
and pseudopodia, while pERK2 is slightly enriched in the PD and thus preferred in the
regulation of the pseudopodia formation in MCF-7 cells (Fig. 3C, D). This suggests that
ERK1 and ERK2 have diverse functions and target distinct substrates leading to
cytoskeletal re-arrangments and subsequent formation of the pseudopodium. Whether
these functions are interchangeable is something that has to be studied further. The
relatively weak increase of pERK2 in PD could possibly explain the low ability of MCF-
7 to migrate and invade; perhaps a bigger increase would be observed in highly
metastatic cells.
Proteomic screens of the pseudopodial proteome have been published from experiments
in COS-7 cells in response to lipopolysaccharide (LPS) [4, 5] and in human astrocytoma
cells [39]. In the present study we used a cell line with low metastatic ability and we
induced migration by activating the endogenous PAR-2 receptor (Fig. 3A). We analysed
the proteins involved in the formation and extension of the pseudopodium after activation
of PAR-2. Subsequent analyses were focused on the proteins found enriched in the PD
fraction as these proteins are more likely to contribute to the formation of the
pseudopodia. Other proteins that are equally distributed in the PD and CB might also play
a role and they can be the subject of further studies, especially of phosphoproteomic
studies [40]. All the proteins confidently found enriched in the pseudopodium are
presented in Table 1 and none of them have been previously described as PAR-2
regulated. Despite our phosphopeptide enrichment step, we did not detect
phosphorylation sites, possibly due to the small size of pseudopodia formed by the MCF-
7 cells producing low protein abundant pseudopodial samples as starting material. Two of
the proteins that are candidates for further studies are nidogen-1 and nidogen-2. After
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
careful inspection of our mass spectrometry data we found that the peptides
corresponding to these proteins were not proteotypic. Therefore, it was not possible to
distinguish whether it is one of the two specific isoforms or both that were identified. In
the tables we have included only nidogen-1 but it is highly likely that both are involved in
pseudopodia formation as they have around 50% sequence similarity and they perform
similar or perhaps identical functions [57]. Kubota et al., proposed a possible function for
nidogen-1 in migration of C. elegans, during the interaction of integrins with the
basement membrane, and that this function is evolutionarily conserved in mammals [41].
Furthermore, nidogen-1 knockout mice presented impaired wound healing [42]. What
makes our finding more intriguing is the recent establishment of nidogen-2 as a
biomarker for ovarian cancer, since it was overexpressed in the serum of women with
ovarian cancer [43].
The PAR-2-regulated signalling pathways represented by the CB- and PD-enriched
proteins are listed in Fig. 4. The results are consistent with the findings of Wang et al. [4]
study, in which EGF, PDGF and Huntington's disease signalling were also enriched in the
PD. In addition, here we show that clathrin-mediated endocytosis as well as heme
biosynthesis, interleukin and PI3 kinase pathways signalling together with dopamine
receptor and JAK/STAT signalling are also important pathways in cancer cell migration.
These new findings are likely to be attributed to the migration of cancer cells specifically.
With respect to the CB-enriched pathways, we found cell cycle-related and various
metabolic pathways, similarly to the Wang et al study [4]. The AP-2 complex large
subunits alpha-1 and beta were found only in PD. The AP-2 complex is localized at the
plasma membrane and is associated with -arrestin and clathrin-mediated endocytosis but
here we show that upon PAR-2-mediated pseudopium formation AP-2 complex and
clathrin signalling are enriched in the PD. The latter strongly suggests that receptor
internalization is a critical process for the promotion of migratory signals. This is in
agreement with previous studies [10, 19] and raises the question of whether blocking
receptor internalization could be used in therapies against metastasis. Furthermore,
although the actin cytoskeleton is heavily regulated in both compartments, the Rho
signalling pathway was strongly enriched in PD showing the importance of this pathway
in cell polarization and invasion, in agreement with others [44].
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
It has been reported by several groups that -arrestin is an important scaffold protein
initiating signalling pathways during receptor internalization via clathrin-coated pits.
Hence, we pulled-down -arrestins after activating the PAR-2 receptor and we identified
-arrestin-interacting proteins. The -arrestin interactome has been studied by Lefkowitz
and colleagues using proteomics downstream of the angiotensin II type 1a receptor in
human embryonics kidney cells (HEK293) [45] and by other groups using other methods
(reviewed in [46-48]), therefore, here we report the first interactome in cancer cells and
upon stimulation of PAR-2.
Several proteins identified in our study were previously known as -arrestin interactors,
such as 14-3-3, serine/threonine kinase 38, clathrin heavy chain 1 and 2, copine, annexin,
fatty acid synthase, ATP synthase and , phosphatases, actins, tubulins, tubulin -3, -8,
F-actin capping protein, myosin-9, filamin, kinesin, dynein, titin, calpain-1 catalytic
subunit, dehydrogenase, phospholipase, tropomyosin, histone H1, heat shock protein 70,
70.1, 90, T-complex protein 1, carboxypeptidase, treacle, nucleophosmin, nucleolin,
hnRNP, ribosomal proteins S3, S7, L7, L19, L22, P0, P1, P2 and others (SI table 4) [45].
In addition, several isoforms of proteins that are known to interact with -arrestins, such
as phosphatases and ribosomal proteins, were also found here. We also excluded proteins
that were found in other proteomic screens as -arrestin-interactors but in our strategy
were considered as background due to their identification in the negative controls (SI
table 11). Also note that in this study, we did not over-express the receptor, reducing the
possibility of unspecific binding due to exogenous protein expression.
Importantly, we identify new interactions, such as TRIM29, glutaredoxin, periplakin and
others, and these interactions might play a role in PAR-2 signalling in cancer. The finding
of alpha-actinin as well as several other actin isoforms in our screens suggests that actin
cytoskeleton and -arrestins interact to manage receptor endocytosis [49] and leading
edge formation [50]. Similarly, their interaction with S100A7 increases the role of -
arrestins in metastatic pathways [51]. It is also shown here that PAR-2 regulates the
activity of kinases such as cyclin-dependent kinase (cdk) 13, N-acetyl-D-glucosamine
kinase and microtubule-associated serine/threonine-protein kinase 2, in a -arrestin-
dependent manner. More specifically, cdk13 and N-acetyl-D-glucosamine kinase are
pulled down with both -arrestins in uninduced conditions but in induced conditions this
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
association is lost. The opposite seems to be the case for microtubule-associated
serine/threonine-protein kinase 2 (Tables 2, 3 and SI Table 9). Another two proteins we
showed here by mass spectrometry and independent co-IPs that are genuine -arrestin-
interacting proteins downstream of PAR-2 are nucleophosmin B23 (NPM1) and heat
shock protein 70 (HSP70) (Fig. 5). This is specifically interesting in the case of NPM1, as
it is a multifunctional protein that is over-expressed in cancer cells, compared to normal
cells, and it is considered a putative therapeutic target for hematological diseases [52-54].
Another protein found in our proteomic screen, the eukaryotic translation initiation factor
3 (eIF3), has been recently found as a -arrestin-2 interactor by another study [55]. This
interaction, which is mediated by epidermal growth factor (EGF) stimulation, promotes
binding of eIF3a to SHC and Raf-1 and subsequent suppression of the ERK pathway
[55]. Whether all these interactions take place in other types of cancer or are also
regulated by other GPCRs is a question that requires further study.
Furthermore, we compared the overlap between the -arrestin-interactors and the PD-
enriched protein screens in order to identify other proteins of special interest (Table 4).
These proteins are very likely to spatiotemporally translocate to the pseudopodium or
retained away from it in a -arrestin-dependent manner. For example, copine, T-plastin,
coatomer subunit beta and LDH-A were found associated with -arrestin-2 in untreated
conditions but when PAR-2 is activated this interaction is lost and the proteins are found
in pseudopodia. Alpha-actinin, AHNAK and elongation factor 1-alpha 1 are likely to be
recruited to the pseudopodia by -arrestins when PAR-2 is activated. Very importantly,
RNA helicase DDX5 has also been found in this overlap. DDX5 is a nuclear DEAD-box
containing protein with roles in development, miRNA pathway, in regulation of
transcription and RNA processing and ribosome biogenesis. It is mainly nuclear but it
was reported to translocate to the cytoplasm in order to recruit beta-catenin back to the
nucleus and control transcription [56]. In our screens, it was found as -arrestin-2 partner
only when cells were treated with FCS. Therefore, as the pseudopodia in our study were
formed upon PAR-2 activation, this shows that DDX5 is enriched at the PD when not
sequestered by -arrestin-2. As an additional validation of our screens, AP-2 complex
subunits alpha-1 and beta were found in both screens.
Conclusion
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
In conclusion, this study presents the proteins and the signalling pathways enriched in the
pseudopodia of migrating breast cancer cells by using pseudopodia purification and mass
spectrometry-based proteomics. Furthermore, by using immunoprecipitation and mass
spectrometry, several PAR-2-regulated -arrestin-1 and -arrestin-2 interactors were
identified and revealed novel functions. This study therefore expanded the possible
functions of -arrestins, especially during breast cancer cell migration, and provides
directions for future research.
Acknowledgment
We acknowledge all members of the Metodiev laboratory for support and useful
discussions. We are grateful to Robert Lefkowitz, for kindly providing the -arrestin-
expressing vectors used in the study, Yoanne Mousseau for technical help and critical
advice in setting up the agarose migration assay. NP is grateful to Daniel Fisher for his
continuous support. We also acknowledge Daniel Fisher, Liliana Krasinska and James
Hutchins for proofreading and for critical recommendations while writing the first
version of the manuscript.
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
Figure legends.Figure 1.
Schematic representation of the experimental strategies performed in this study.
Figure 2.
Endogenous expression of PAR-2 in MCF7 cells and ERK activity in untreated, FCS
(10%) or PAR-2 (50 M) treated conditions. (A) Detection of PAR-2 mRNA in MCF7
cells by reverse transcription PCR. (B) Levels of ERK activity upon treatment with P2AP
(50 M) or FCS. Cells were serum-starved and then treated or not with the indicated
agents for the indicated times and pERK was detected by anti-phospho p44/p42 MAPK
(Cell Signaling) in clear lysates by western blotting. Tubulin was used as loading control
Figure 3.
Effect of gradient concentrations of P2AP on chemotaxis and on ERK activity in MCF-7
cells. (A) Under agarose migration assay: Three wells were generated essentially as
described in [28]. cells were seeded in the middle well while 50 M P2AP or RPMI only
were added in the side wells. The chemoattractant diffused through the agarose creating a
gradient to which cells responded by migrating towards the side with the chemoattractant.
The image is representative of 3 individual experiments. Bar: 100 m; (B) The pools of
proteins from cell bodies (CB) or pseudopodia (PD) separated by the pseudopodia
purification assay were analysed by 10% SDS-PAGE. Arrow indicates the histone
proteins. Lines indicate the sliced gel pieces from which proteins were digested and
analysed by mass spectrometry. (C) Immunoblots of PARP-1 for validation of PD
purification (upper panel) and pERK (lower panel) in PD and CB. (D) Levels of
pERK1/2, pERK1 and pERK2 in PD and CB.
Figure 4.
Comparison of the protein identifications from the 2 different proteomic workflows used
to identify PD and CB enriched proteins (see text for details). In parallel, proteins are
categorized based on the PD/CB ratio, with the PD enriched proteins to the right-hand
side and CB-enriched to the left-hand side. The most enriched signalling pathways
represented by these proteins in each fraction are listed; the complete PANTHER
pathway analysis is shown in SI figure 2.
485486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
Figure 5.
Validation of nucleophosmin (A) and heat shock protein 70 (HSP70; B) as -arrestin
interacting proteins by co-immunoprecipitation (co-IP). Control experiments were co-IPs
with -FLAG beads from untransfected cells or with unreactive protein A/G beads from
FLAG-tagged -arrestin-transfected cells.
SI Figure 1.
PANTHER pathway analysis of proteins enriched in the pseudopodia (left-hand panel) or
cell bodies (right-hand panel) [34]. Numbers in square brackets indicate the percentage of
the number of proteins corresponding to this pathway.
SI Figure 2
Gene Ontology (GO) terms of PD- and CD-enriched proteins in pie charts generated by
PANTHER Classification System (http://www.pantherdb.org/).
SI Figure 3
Ingenuity Pathway Analysis of proteins that co-immunoprecipitate with -arrestin-1 (dark
blue bars) or -arrestin-2 (light blue bars).
SI Figure 4 A-I.
Gene Ontology (GO) terms Molecular Function and Biological Process of -arrestin-
interacting proteins, upon treatment with FCS, P2AP or not treated, in pie charts
generated by PANTHER Classification System (http://www.pantherdb.org/).
References
[1] Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science. 2003;302:1704-9.[2] Devreotes P, Janetopoulos C. Eukaryotic chemotaxis: distinctions between directional sensing and polarization. Journal of Biological Chemistry. 2003;278:20445-8.[3] Chodniewicz D, Klemke RL. Guiding cell migration through directed extension and stabilization of pseudopodia. Experimental Cell Research. 2004;301:31-7.[4] Wang Y, Ding SJ, Wang W, Jacobs JM, Qian WJ, Moore RJ, et al. Profiling signaling polarity in chemotactic cells. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:8328-33.
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536537538539540541542543544
[5] Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, et al. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci U S A. 2010;107:10920-5.[6] Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. European Journal of Biochemistry. 1995;232:84-9.[7] Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. American Journal of Physiology. 1998;274:C1429-52.[8] Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69-86.[9] D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. American Journal of Pathology. 2001;158:2031-41.[10] Ge L, Shenoy SK, Lefkowitz RJ, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. Journal of Biological Chemistry. 2004;279:55419-24.[11] Ikeda O, Egami H, Ishiko T, Ishikawa S, Kamohara H, Hidaka H, et al. Signal of proteinase-activated receptor-2 contributes to highly malignant potential of human pancreatic cancer by up-regulation of interleukin-8 release. International Journal of Oncology. 2006;28:939-46.[12] Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004;2:395-402.[13] Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103:3029-37.[14] Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Research. 2001;61:5933-40.[15] Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Research. 2006;66:307-14.[16] Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annual Review of Pharmacology and Toxicology. 1998;38:289-319.[17] Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiological Reviews. 2004;84:579-621.[18] DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. Journal of Cell Biology. 2000;148:1267-81.[19] Ge L, Ly Y, Hollenberg M, DeFea K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. Journal of Biological Chemistry. 2003;278:34418-26.[20] Alldridge L, Metodieva G, Greenwood C, Al-Janabi K, Thwaites L, Sauven P, et al. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J Proteome Res. 2008;7:1458-69.[21] Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics. in print.[22] Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis.
545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592
Proceedings of the National Academy of Sciences of the United States of America. 1999;96:3712-7.[23] Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-61.[24] Blackhart BD, Emilsson K, Nguyen D, Teng W, Martelli AJ, Nystedt S, et al. Ligand cross-reactivity within the protease-activated receptor family. Journal of Biological Chemistry. 1996;271:16466-71.[25] Compton SJ, Cairns JA, Palmer KJ, Al-Ani B, Hollenberg MD, Walls AF. A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. Journal of Biological Chemistry. 2000;275:39207-12.[26] Inoue H, Nojima H, Okayama H. High efficiency transformation of Escherichia coli with plasmids. Gene. 1990;96:23-8.[27] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-5.[28] Mousseau Y, Leclers D, Faucher-Durand K, Cook-Moreau J, Lia-Baldini AS, Rigaud M, et al. Improved agarose gel assay for quantification of growth factor-induced cell motility. Biotechniques. 2007;43:509-16.[29] Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1:2856-60.[30] Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, et al. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res. 2006;5:112-21.[31] Keller A, Eng J, Zhang N, Li XJ, Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol Syst Biol. 2005;1:2005 0017.[32] Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003;75:4646-58.[33] Liu H, Sadygov RG, Yates JR, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Analytical Chemistry. 2004;76:4193-201.[34] Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 2003;31:334-41.[35] Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032-7.[36] Brahmbhatt AA, Klemke RL. ERK and RhoA differentially regulate pseudopodia growth and retraction during chemotaxis. Journal of Biological Chemistry. 2003;278:13016-25.[37] Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. Journal of Cellular Physiology. 1992;150:534-44.[38] Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest. 2003;123:765-71.[39] Beckner ME, Chen X, An J, Day BW, Pollack IF. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest. 2005;85:316-27.[40] Thingholm TE, Jensen ON, Larsen MR. Analytical strategies for phosphoproteomics. Proteomics. 2009;9:1451-68.
593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640
[41] Kubota Y, Ohkura K, Tamai KK, Nagata K, Nishiwaki K. MIG-17/ADAMTS controls cell migration by recruiting nidogen to the basement membrane in C. elegans. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:20804-9.[42] Baranowsky A, Mokkapati S, Bechtel M, Krugel J, Miosge N, Wickenhauser C, et al. Impaired wound healing in mice lacking the basement membrane protein nidogen 1. Matrix Biology. 2008;29:15-21.[43] Kuk C, Gunawardana CG, Soosaipillai A, Kobayashi H, Li L, Zheng Y, et al. Nidogen-2: a new serum biomarker for ovarian cancer. Clinical Biochemistry. 2010;43:355-61.[44] Vishnubhotla R, Sun S, Huq J, Bulic M, Ramesh A, Guzman G, et al. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest. 2007;87:1149-58.[45] Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A. 2007;104:12011-6.[46] Lefkowitz RJ, Rajagopal K, Whalen EJ. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell. 2006;24:643-52.[47] Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-7.[48] Min J, Defea K. beta-arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol.80:760-8.[49] Lamaze C, Fujimoto LM, Yin HL, Schmid SL. The actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells. J Biol Chem. 1997;272:20332-5.[50] Min J, Defea K. beta-arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol. 2011;80:760-8.[51] Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res.72:604-15.[52] Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene. 2011;30:2595-609.[53] Okuwaki M. The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem. 2008;143:441-8.[54] Yung BY. Oncogenic role of nucleophosmin/B23. Chang Gung Med J. 2007;30:285-93.[55] Xu TR, Lu RF, Romano D, Pitt A, Houslay MD, Milligan G, et al. Eukaryotic translation initiation factor 3, subunit a, regulates the extracellular signal-regulated kinase pathway. Mol Cell Biol.32:88-95.[56] Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell. 2006;127:139-55.[57] Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafa R, et al. Nidogen 1 and 2 gene promoters are abberantly methylated in human gastointestinal cancer. Mol Cancer. 2007;6:17
641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679
680